Business
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia.\n\n\n“Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry,” said Mark Schneyer, Executive Vice President, Chief Financial Officer. “His deep experience working within companies and on Wall Street, his strong network of relationships, and his proven expertise in building shareholder value will be instrumental as we continue to advance our global business strategy to deliver important therapeutics for central nervous system disorders.”\n\n\nMr. Kildani joins Acadia most recently from Halozyme Therapeutics, where he served as Vice President, Investor Relations and Corporate Communications and helped guide the company’s transition from early drug development stage to a profitable biopharmaceutical company. Prior to Halozyme, Al oversaw investor relations and business development at Vital Therapies, Inc., and investor relations at Hologic, Inc. and Gen-probe Incorporated. Prior to his transition to the life sciences industry, Al spent over a dozen years on Wall Street serving as an analyst and portfolio manager at Stark Investments, and previously as a sell-side analyst with C.E. Unterberg, Towbin and Pacific Growth Equities LLC. Mr. Kildani earned a bachelor’s degree in Economics and Finance from Boston College.\n\n\n“I’m excited to join Acadia during this time of transformational growth as we deliver two important and commercially available therapeutics in areas of high unmet medical need to the patient community,” said Mr. Kildani. “The ongoing strength of the DAYBUE™ (trofinetide) launch, combined with our increasingly cash-flow positive NUPLAZID® (pimavanserin) franchise and our deep pipeline with upcoming data readouts position Acadia for long-term growth as we develop new therapies for patients and their families.”\n\n\nAbout NUPLAZID® (pimavanserin)\n\n...